ASH 2023: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Patients With Mantle Cell Lymphoma
Benefits also seen for complete response and time to next treatment with relapsed/refractory disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.